{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:48:45Z","timestamp":1781765325471,"version":"3.54.5"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1186","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite previous concerns about ocular side effects related to amiodarone, the relationship between amiodarone and cataract remains uncertain. Therefore, this study aimed to assess the potential association between amiodarone use and the subsequent risk of cataract, taking into account potential confounders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This population-based, active comparator-controlled cohort study utilized the data from the Taiwan National Health Insurance program and involved adults over 40\u00a0years old between 2001 and 2013. We analyzed 12 055 new amiodarone users and contrasted them with a propafenone user cohort. The primary outcome was the incidence of cataract. Inverse-probability treatment-weighting (IPTW) was further used to eliminate the potential confounding effects, and Cox proportional-hazard regression analyses were performed to calculate the risk of cataract. Serial subgroup analyses were also performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the main analysis, amiodarone users did not exhibit a significant causal relationship in both full cohort [adjusted hazard ratio (aHR): 0.994, 95% confidence interval (CI): 0.913\u20131.082] and IPTW cohort (IPTW-aHR 0.977, 95% CI: 0.900\u20131.060). Furthermore, it is important to highlight a significantly reduced risk of cataract among patients with heart failure (IPTW-aHR 0.708, 95% CI: 0.554\u20130.905) and during the 2-year follow-up period (IPTW-aHR 0.889, 95% CI: 0.794\u20130.996), implying potential advantages linked to the use of amiodarone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The study found no increased risk of cataract with amiodarone, one of the most frequently used antiarrhythmic medications, compared to the use of propafenone. Future research is recommended to explore potential mechanisms and their implications for clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/postmj\/qgae034","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T16:22:36Z","timestamp":1710951756000},"page":"584-591","source":"Crossref","is-referenced-by-count":1,"title":["Association between amiodarone use and risk of cataract: a population-based active-comparator study"],"prefix":"10.1093","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5996-2879","authenticated-orcid":false,"given":"Sheng-Yin","family":"To","sequence":"first","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center , Taipei 114 , Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center , Taipei 114 , Taiwan"},{"name":"School of Public Health, National Defense Medical Center , Taipei 114 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Ting","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Defense Medical Center, Tri-Service General Hospital , Taipei 114 , Taiwan"},{"name":"National Defense Medical Center, Graduate Institute of Medical Sciences , Taipei 114 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Cheng","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Taichung Armed Forces General Hospital , Taichung 411 , Taiwan"},{"name":"Department of Medical Education and Research, Taichung Armed Forces General Hospital , Taichung 411 , Taiwan"},{"name":"School of Medicine, National Defense Medical Center , Taipei 114 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Ting","family":"Pan","sequence":"additional","affiliation":[{"name":"Bartlett School, Institute of Environmental Design and Engineering, UCL , London, WC1E 6BT , United Kingdom"},{"name":"National Defense Medical Centre, Graduate Institute of Aerospace and Undersea Medicine , Taipei 114 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Liang","family":"Wen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center , Taipei 114 , Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center , Taipei 114 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senyeong","family":"Kao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center , Taipei 114 , Taiwan"},{"name":"School of Public Health, National Defense Medical Center , Taipei 114 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-7408","authenticated-orcid":false,"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center , Taipei 114 , Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center , Taipei 114 , Taiwan"},{"name":"Department of Pharmacy Practice, Tri-Service General Hospital , Taipei 114 , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"2024072207011057300_ref1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/ICU.0000000000000340","article-title":"The global state of cataract blindness","volume":"28","author":"Lee","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"2024072207011057300_ref2","doi-asserted-by":"crossref","first-page":"e114012","DOI":"10.1371\/journal.pone.0114012","article-title":"Hypertension and risk of cataract: a meta-analysis","volume":"9","author":"Yu","year":"2014","journal-title":"PLoS One"},{"key":"2024072207011057300_ref3","doi-asserted-by":"crossref","first-page":"100008","DOI":"10.1016\/j.aopr.2021.100008","article-title":"Cataract: advances in surgery and whether surgery remains the only treatment in future","volume":"1","author":"Chen","year":"2021","journal-title":"Adv Ophthalmol Pract Res"},{"key":"2024072207011057300_ref4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0002-9394(03)00226-5","article-title":"Cataract treatment in the beginning of the 21st century","volume":"136","author":"Olson","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"2024072207011057300_ref5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.333.7559.128","article-title":"Cataract and surgery for cataract","volume":"333","author":"Allen","year":"2006","journal-title":"BMJ"},{"key":"2024072207011057300_ref6","doi-asserted-by":"crossref","first-page":"108705","DOI":"10.1016\/j.exer.2021.108705","article-title":"Protein posttranslational modification (PTM) by glycation: role in lens aging and age-related cataractogenesis","volume":"210","author":"Fan","year":"2021","journal-title":"Exp Eye Res"},{"key":"2024072207011057300_ref7","article-title":"Association between cataract and risk of incident atrial fibrillation: a nationwide population-based retrospective cohort study","volume":"92","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2024072207011057300_ref8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.amjmed.2015.08.039","article-title":"Practical management guide for clinicians who treat patients with amiodarone","volume":"129","author":"Epstein","year":"2016","journal-title":"Am J Med"},{"key":"2024072207011057300_ref9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMct065916","article-title":"Amiodarone for atrial fibrillation","volume":"356","author":"Zimetbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"2024072207011057300_ref10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(94)91895-3","article-title":"Randomised trial of low-dose amiodarone in severe congestive heart failure","volume":"344","author":"Doval","year":"1994","journal-title":"Lancet"},{"key":"2024072207011057300_ref11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(97)05281-1","article-title":"Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"2024072207011057300_ref12","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/hrt.2008.152652","article-title":"Amiodarone: an effective antiarrhythmic drug with unusual side effects","volume":"96","author":"Erven","year":"2010","journal-title":"Heart"},{"key":"2024072207011057300_ref13","doi-asserted-by":"crossref","first-page":"104167","DOI":"10.1016\/j.amsu.2022.104167","article-title":"CLInical profile and side effects of chronic use of oral amiodarone in cardiology outpatients department (CLIPSE-A study)-a prospective observational study","volume":"80","author":"Fatima","year":"2022","journal-title":"Ann Med Surg"},{"key":"2024072207011057300_ref14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1540-8159.1998.tb01068.x","article-title":"Adverse effects of amiodarone","volume":"21","author":"Jafari-Fesharaki","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"key":"2024072207011057300_ref15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3904\/kjim.2014.29.5.571","article-title":"Adverse effects of long-term amiodarone therapy","volume":"29","author":"Park","year":"2014","journal-title":"Korean J Intern Med"},{"key":"2024072207011057300_ref16","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.12659\/MSM.890881","article-title":"Cutaneous adverse reactions of amiodarone","volume":"20","author":"Jaworski","year":"2014","journal-title":"Med Sci Monit"},{"key":"2024072207011057300_ref17","first-page":"2189","article-title":"Amiodarone: guidelines for use and monitoring","volume":"68","author":"Siddoway","year":"2003","journal-title":"Am Fam Physician"},{"key":"2024072207011057300_ref18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/OPX.0000000000001534","article-title":"Ocular adverse effects of amiodarone: a systematic review of case reports","volume":"97","author":"Alshehri","year":"2020","journal-title":"Optom Vis Sci"},{"key":"2024072207011057300_ref19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1034\/j.1600-0420.2002.800112.x","article-title":"Visual functions and adverse ocular effects in patients with amiodarone medication","volume":"80","author":"Ik\u00e4heimo","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"2024072207011057300_ref20","doi-asserted-by":"crossref","first-page":"A1414","DOI":"10.1016\/j.chest.2021.07.1293","article-title":"A review of amiodarone side effects in a cohort of patients: a quality improvement project","volume":"160","author":"Lantz","year":"2021","journal-title":"Chest"},{"key":"2024072207011057300_ref21","doi-asserted-by":"crossref","first-page":"bcr2016217436","DOI":"10.1136\/bcr-2016-217436","article-title":"Short-term treatment with oral amiodarone resulting in bilateral optic neuropathy and permanent blindness","volume":"2017","author":"Knudsen","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2024072207011057300_ref22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/j.1875-9114.1985.tb03434.x","article-title":"Amiodarone: pharmacology and antiarrhythmic and adverse effects","volume":"5","author":"Naccarelli","year":"1985","journal-title":"Pharmacotherapy"},{"key":"2024072207011057300_ref23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.wno.0000177290.09649.38","article-title":"Amiodarone and optic neuropathy: the heart of the matter","volume":"25","author":"Murphy","year":"2005","journal-title":"J Neuroophthalmol"},{"key":"2024072207011057300_ref24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan\u2019s national health insurance research database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2024072207011057300_ref25","volume-title":"Epidemiol Health"},{"key":"2024072207011057300_ref26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0735-1097(02)02705-5","article-title":"Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis","volume":"41","author":"Chevalier","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2024072207011057300_ref27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5090\/kjtcs.2016.49.3.177","article-title":"Amiodarone versus propafenone to treat atrial fibrillation after coronary artery bypass grafting: a randomized double blind controlled trial","volume":"49","author":"Nemati","year":"2016","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"2024072207011057300_ref28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcrc.2017.04.027","article-title":"Propafenone for supraventricular arrhythmias in septic shock\u2014comparison to amiodarone and metoprolol","volume":"41","author":"Balik","year":"2017","journal-title":"J Crit Care"},{"key":"2024072207011057300_ref29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024072207011057300_ref30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2024072207011057300_ref31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2024072207011057300_ref32","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2024072207011057300_ref33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024072207011057300_ref34","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0161-6420(98)99049-2","article-title":"Medications and cataract: the blue mountains eye study","volume":"105","author":"Cumming","year":"1998","journal-title":"Ophthalmology"},{"key":"2024072207011057300_ref35","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1001\/archopht.1983.01040020556010","article-title":"Amiodarone-induced lens opacities","volume":"101","author":"Flach","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"2024072207011057300_ref36","first-page":"468","article-title":"Amiodarone keratopathy and lens opacities","volume":"56","author":"Dolan","year":"1985","journal-title":"Optometry"},{"key":"2024072207011057300_ref37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1076\/opep.10.4.227.15905","article-title":"Cardiovascular disease, vascular risk factors and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study","volume":"10","author":"Younan","year":"2003","journal-title":"Ophthalmic Epidemiol"},{"key":"2024072207011057300_ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2415-14-128","article-title":"Time trend of prevalence of self-reported cataract and its association with prolonged sitting in Taiwan from 2001 and 2013","volume":"14","author":"Shih","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"2024072207011057300_ref39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/eurheartj\/ehp100","article-title":"Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials","volume":"30","author":"Piccini","year":"2009","journal-title":"Eur Heart J"},{"key":"2024072207011057300_ref40","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM200003303421302","article-title":"Amiodarone to prevent recurrence of atrial fibrillation","volume":"342","author":"Roy","year":"2000","journal-title":"N Engl J Med"},{"key":"2024072207011057300_ref41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7326\/0003-4819-143-5-200509060-00008","article-title":"Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis","volume":"143","author":"Aasbo","year":"2005","journal-title":"Ann Intern Med"},{"key":"2024072207011057300_ref42","doi-asserted-by":"crossref","first-page":"100039","DOI":"10.1194\/jlr.TR120000874","article-title":"Lipid conformational order and the etiology of cataract and dry eye","volume":"62","author":"Borchman","year":"2021","journal-title":"J Lipid Res"},{"key":"2024072207011057300_ref43","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1194\/jlr.M079368","article-title":"Whales, lifespan, phospholipids, and cataracts","volume":"58","author":"Borchman","year":"2017","journal-title":"J Lipid Res"},{"key":"2024072207011057300_ref44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archopht.124.1.79","article-title":"Development of cataract and associated risk factors: the visual impairment project","volume":"124","author":"Mukesh","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"2024072207011057300_ref45","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/bjo.2008.153379","article-title":"Use of antihypertensive medications and topical beta-blockers and the long-term incidence of cataract and cataract surgery","volume":"93","author":"Kanthan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"2024072207011057300_ref46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0735-1097(98)00678-0","article-title":"Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study","volume":"33","author":"Kochiadakis","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2024072207011057300_ref47","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.amjcard.2007.01.059","article-title":"A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation","volume":"99","author":"Kochiadakis","year":"2007","journal-title":"Am J Cardiol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/100\/1186\/584\/58581977\/qgae034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/100\/1186\/584\/58581977\/qgae034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T07:16:02Z","timestamp":1721632562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/100\/1186\/584\/7632420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":47,"journal-issue":{"issue":"1186","published-online":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgae034","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,3,20]]}}}